Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced the appointments of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, strengthening its expertise in biotechnology, drug delivery, and central nervous system clinical development. The company, which is advancing a pipeline of novel serotonergic agonists (NSAs), aims to address unmet needs in mental health, including major depressive disorder and generalized anxiety disorder.
Dr. Robert Langer, a renowned figure in biotechnology and drug delivery, brings decades of experience from the Massachusetts Institute of Technology, where he has pioneered innovations in controlled-release systems and tissue engineering. His contributions to the field have been recognized with numerous awards, including the National Medal of Science. Dr. Stephen Brannan, a psychiatrist and clinical development expert, has extensive experience in CNS drug development, having led programs at Sunovion Pharmaceuticals and other organizations. His expertise will be instrumental as Helus Pharma advances its pipeline candidates, including HLP003, currently in Phase 3 for adjunctive treatment of major depressive disorder, and HLP004, in Phase 2 for generalized anxiety disorder.
The appointments underscore Helus Pharma's commitment to disciplined, evidence-based drug development. The company's proprietary NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, offering potential durable improvements in mental health. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to address a significant unmet need. The addition of Dr. Langer and Dr. Brannan is expected to accelerate the company's research and development efforts.
Helus Pharma, the commercial operating name of Cybin Inc., operates in Canada, the United States, the United Kingdom, and Ireland. The company's focus on developing novel treatments for mental health conditions aligns with a growing recognition of the need for innovative therapies. For more information, visit the company's website at www.helus.com or follow the team on social media platforms. The latest news and updates are available in the company's newsroom at https://ibn.fm/HELP.
